Cymax (160980) has 8 disclosed insider purchases and 3 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩1.3B ($883K) in reported transaction value. The earliest filing StockDrifts holds for Cymax is dated 2024-03-15; the most recent is 2026-03-18. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +113.27%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | BUY | 상속 | 정혜은 Jeong Hye-eun | CEO | 532.9K | - | - | - |
| 2026-03-18 | SELL | 피상속 | 정구용 Jeong Gu-yong | Former) CEO and Chairman | -532.9K | - | - | - |
| 2025-08-19 | BUY | 시간외매매 | 인지컨트롤스 Cognitive Controls | - | 703.8K | ₩12,260 | +67.2% | ₩8.6B ($6.0M) |
| 2024-12-11 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 22.2K | ₩7,840 | +161.5% | ₩174M ($121K) |
| 2024-12-10 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 35.9K | ₩7,730 | +165.2% | ₩278M ($193K) |
| 2024-12-09 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 378 | ₩7,500 | +173.3% | ₩3M ($2K) |
| 2024-12-06 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 11.8K | ₩8,000 | +156.3% | ₩94M ($65K) |
| 2024-12-05 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 5.7K | ₩8,040 | +155.0% | ₩46M ($32K) |
| 2024-12-04 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 14.1K | ₩8,020 | +155.6% | ₩113M ($79K) |
| 2024-12-03 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 5.8K | ₩8,040 | +155.0% | ₩46M ($32K) |
| 2024-11-28 | BUY | Market Buy | 정혜은 Jeong Hye-eun | CEO | 162 | ₩8,480 | +141.8% | ₩1M ($954) |
| 2024-03-19 | SELL | Market Sell | 전인택 Jeon In-taek | Chief Medical Officer | -8.6K | ₩19,300 | -6.2% | ₩166M ($115K) |
| 2024-03-18 | SELL | Market Sell | 전인택 Jeon In-taek | Chief Medical Officer | -8.9K | ₩19,300 | -6.2% | ₩172M ($119K) |
| 2024-03-15 | SELL | Market Sell | 전인택 Jeon In-taek | Chief Medical Officer | -9.2K | ₩19,490 | -5.2% | ₩179M ($124K) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Cymax. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.